Abstract
The results of the analysis of vaccination against hepatitis B performed in 2,000 persons of high-risk groups in Croatia are described. All susceptible non-immunocompromised persons (HBsAg, anti-HBs, and anti-HBc negative) received either plasma-derived vaccine (HB-Vax MSD, 20 µg per dose) or recombinant HB vaccine (ENGERIX-B, SKB, 20 µg per dose) according to a 0,1 and 6-month schedule. Hemodialysis patients received four doses of HB vaccine (40 µg per dose). Seroconversion occurred in 98% of health care workers, 98.5% of family members of HBsAg chronic carriers, 98% of infants born to HBsAg carrier-mothers and 92% of hemodialysis patients. The percentage of poor-responders (titer of anti-BHs=1−10 mIU/ml) for the groups was 2, 2, 8 and 20%, respectively, while low-responders (titer of anti-BHs=10.1−100 mIU/ml) were 5, 4.5, 12 and 26%, respectively. A significant prevalence of non-responders, poor-responders and low-responders among male health care workers was noticed (p=0.01, 0.026 and 0.002, respectively). Females significantly prevailed among excellent-responders (p=0.0039). In hemodialysis patients, there were 8% non-responders, 19.5% poor-responders, and 26% low-responders. A significant difference between the percentage of good-responders (titer of anti-HBs=101−1,000 mIU/ml) and excellent-responders (titer of anti-HBs over 1,000 mIU/ml) among health care workers and hemodialysis patients was documented (91% versus 46.5%,p<0.0001). The combined passive-active immunization (hyperimmune hepatitis B globulin + hepatitis B vaccine) was effective in 98% of infants born to HBsAg carrier-mothers, and only one boy developed sub-clinical HBV infection (HBsAg and anti-HBc positive findings with normal ALT-values). Among these infants of seven months of age, a significantly higher percentage of poor-, and low-responders (20%) than that seen among older, non-immunocompromised persons (7% and 8% respectively) was noticed (p=0.0241). Out of 20 initially non-responders, seroconversion occurred in 11 of them (54%) after two ‘booster’ doses of Engerix-B (20 µg per dose). By the use of the same procedure, a raised titer of anti-BHs was present in 92% of initially poor-responders and 100% of initially low-responders. Needle-stick exposure to HBsAg-positive blood occurred in 9 health care workers in the course of their vaccination and in 14 who had completed vaccination. Neither manifest nor subclinical HBV infections have developed among them. On the contrary, two surgeons who omitted the third dose of vaccine developed acute icteric hepatitis B two years later. Thus, complete vaccination (at 0, 1 and 6 months − 20 µg per dose) for non-immunocompromised persons gave good or excellent response in over 90% of recipients. In hemodialysis patients, the results are poorer irrespective of more and higher doses of HB vaccine.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Alter MJ. Community acquired viral hepatitis B and C in the United States. Gut 1993; 34 (Suppl 2): 17–19.
Krugman S. The newly licensed hepatitis B vaccine: Characteristics and indications for use. JAMA 1982; 247: 2012–2015.
Margolis HS, Alter MJ, Hadler SC. Hepatitis B: evolving epidemiology and implications for control. Semin Liver Dis 1991; 11: 84–92.
Szmuness W, Stevens CE, Harley EJ, et al. Hepatitis B vaccine. Demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med 1980; 303: 833–841.
Deinhardt F. Vaccination against viral hepatitis. Infection 1982; 10: 55–57.
Schoub BD, Johnson S, McAnerney JM, et al. Integration of hepatitis B vaccination into rural African primary health care programmes. Br Med J 1991; 302: 313–316.
Palmović D. Treatment and prevention of viral hepatitis. Liječ Vjes 1986; 108: 95–100.
Burden AD, Whorwell PJ. Poor uptake of hepatitis B immunization amongst hospital-based health care staff. Postgrad Med J 1991; 67: 256–258.
Fayol V, Cotisson A, Jullien C, Rotivel Y, Lery L, Ville G. Vaccination contre le virus de l'hepatite B al'institute Pasteur de Lyon. Bilance de sept ans. Pathol Biol 1991; 39: 686–691.
Palmović D. Prevention of hepatitis B infection in health care workers after accidental exposure. J Infect 1987; 15: 221–224.
Rogan PD, Duguid JKM. Immunisation of staff of a regional blood transusion centre with a recombinant hepatitis B vaccine. J Infect 1991; 22: 5–9.
Chernesky MA, Blajchman MA, Castriciano S, Basbaum J, Spiak C, Mahony JB. Analysis of a pregnancy-screening and neonatal-immunisation program for hepatitis B in Hamilton, Ontario, Canada, 1977–1978. J Med Virol 1991; 35: 50–54.
Coutinho RA, Lelie N, van Lent PA, et al. Efficacy of heat inactivated hepatitis B vaccine in male homosexuals: Outcome of a placebo controlled double blind trial. Brit Med J 1983; 286: 1305–1308.
Kruskall MS, Alper CA, Awdeh Z, Yunis EJ, Marcus-Bagley D. The immune response to hepatitis B vaccine in humans: inheritance patterns in families. J Exp Med 1992; 175: 495–502.
Stroffolini T, Pasquini P and Collaborating Group. Five years of vaccination campaign against hepatitis B in Italy in infants of hepatitis B surface antigen carrier mothers. Ital J Gastroenterol 1990; 22: 195–197.
Desmyter J, De Groote G, Colaert J, et al. Efficacy of heat-inactivated hepatitis B vaccine in hemodialysis patients and staff. Double-blind placebo-controlled trial. Lancet 1983 (ii): 1323–1327.
Palmović D, Vitas B, Doko A, et al. Seroresponse to hepatitis B vaccine in patients and staff members of the centre for hemodialysis, Karlovac. Liječ Vjesn 1989; 111: 480–484.
Palmović D, Crnjaković-Palmović J. Prevention of hepatitis B virus (HBV) infection in health-care workers after accidental exposure: A comparison of two prophylactic schedules. Infection 1993; 21: 42–45.
Vodopija I, Ljubičić M, Baklaić Ž, et al. Post-exposure prophylaxis for hepatitis B. Lancet 1989 (ii): 1161–1162 (Letter).
Sherlock S. Different hepatitis B vaccine. Scand J Infect Dis 1983; 38 (suppl): 13–16.
Allegra V, Vasile A, Maschio M, Mengozzi G. Immune response after vaccination with recombinant hepatitis surface antigen in maintenance hemodialysis patients and healthy controls. Nephron 1992; 61: 339–340.
Bhatti N, Gilson RJC, Beecham M, et al. Failure to deliver hepatitis B vaccine: Confessions from a genitourinary medicine clinic. Br Med J 1991; 303: 97–101.
Carletti P, Bibiano L, Boggi R, et al. HBV infection in hemodialysis: Monitoring and prevention. Nephron 1992; 61: 269–270.
Dentico P, Volpe A, Buongiorno R, et al. Immunogenicity and efficacy of anti-hepatitis B vaccines in hemodialysis patients. Nephron 1992; 61: 324–325.
Mioli VA, Balestra E, Bibiano L, et al. Epidemiology of viral hepatitis in dialysis centers: A national survey. Nephron 1992; 61: 278–283.
Oguchi H, Miyasaka M, Tokunaga S, et al. Hepatitis virus infection (HBV and HCV) in eleven Japanese hemodialysis units. Clin Nephrol 1992; 38: 36–43.
Marangi AL, Giordano R, Mantanaro A, et al. A successful two-step integrated protocol of anti-HBV vaccination in chronic uremia. Nephron 1992; 61: 331–332.
Leu LL, Shanahan EM. Hepatitis B vaccination. Br Med J 1992; 305: 1295–1296.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Palmović, D., Crnjaković-Palmović, J. Vaccination against hepatitis B: Results of the analysis of 2000 population members in Croatia. Eur J Epidemiol 10, 541–547 (1994). https://doi.org/10.1007/BF01719570
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01719570